Xeltis

Xeltis are looking forward to attending and presenting at The International Society for Applied Cardiovascular Biology (ISACB) 19th Biennial Meeting in Vienna from October 5 - 8. The details of the presentations are as follows: XABG: A Restorative Polymeric Coronary Artery Bypass Conduit  💬Session 2: Pre-clinical Novelties in Vascular Tissue Engineering 👤Martijn Cox, Co-Founder 📅 Saturday, 5 October | 🕔 15:00 - 17:10 CEST Rat infection model supports improved infection resistance of restorative aXess conduits compared to ePTFE controls  💬Session 11: Cardiac and Vascular Remodeling 👤Hannah Bauer, Preclinical Development Scientist 📅 Tuesday, 8 October | 🕔 08:30 - 10:30 CEST Clinical translation of Restorative Vascular Conduits: Update on progress and insights 💬Session 12: New Opportunities and Challenges in Translational Innovation  👤Martijn Cox, Co-Founder 📅 Tuesday, 8 October | 🕔 11:00 - 12:30 CEST Make sure to come along to these insightful presentations or get in touch if you would like to meet a member of the team! #vascularaccess #dialysis #ISACB

This week, from October 3-5, Xeltis will be attending the Controversies in Dialysis Access (CiDA) Symposium in Washington, DC. This meeting brings together Surgeons, Nephrologists, Interventional Radiologists, and dialysis staff to share insights and experiences on the complexities of vascular access for dialysis. By listening to diverse perspectives, this symposium explores key challenges and advances in dialysis treatments, improving care for patients. Leading KOL Dr Robert Shahverdyan, MD 🇦🇲🇩🇪 will be presenting at the conference! 🎤 Innovative Breakthroughs in Dialysis: A Novel Restorative Conduit for Dialysis Access 📅Saturday, 5 October 🕔9:12 AM - 9:20 AM PDT We’re excited to join the conversation and share the Xeltis mission of addressing unmet medical needs to enhance the lives of patients worldwide. #CiDA2024 #Dialysis #VascularAccess

This Sunday is #WorldHeartDay and Xeltis is proud to support the World Heart Federation's global campaign to raise awareness about the importance of heart health ❤️🌎 Cardiovascular disease (#CVD) is the leading cause of death globally, and combined with heart attacks, strokes, and heart failure, these conditions claim more than 20.5 million lives every year.   At Xeltis, we're leveraging Nobel prize-backed science to pioneer innovative restorative vascular implants addressing this critical unmet medical need, improving the lives of patients worldwide.   Our coronary bypass conduit, XABG, has unique regenerative properties, enabling living tissue to replace it over time. Now in a first-in-human study, XABG has the potential to transform the bypass surgery landscape, eliminating the need for vein harvesting, easing the burden on patients, and reducing the immense strain on global healthcare systems.   Learn more about how we are reshaping the treatment of cardiovascular disease and other areas of high unmet need using the link in the first comment below.

This week Xeltis will be attending the European Society for Vascular Surgery Annual Meeting from 24 - 27 September in Kraków, Poland. We are looking forward to connecting with world-renowned vascular surgeons, researchers, and practitioners, while participating in hands-on workshops, thought-provoking keynote speeches and engaging in discussions that are shaping the future of vascular surgery. CMO Paulo Neves will be in attendance, alongside Senior R&D Manager Wian van den Bergh and R&D Engineer Bilal Enes Okatar. Be sure to reach out to a member of the team to learn more about our transformative implants! #ESVS2024 #VascularSurgery

See our CEO, Eliane Schutte, this week at LSI Europe where she participated in a panel session and delivered a company presentation.   On Tuesday, Eliane joined the panel 'The Art and Science of Cross-Border Business Development and Licensing' sharing her expertise alongside top industry leaders in a thought-provoking discussion.   On Wednesday, she delivered an in-depth presentation on Xeltis, highlighting our transformative vascular implants and how they support the natural development of living, long lasting tissue - showcasing our innovative approach to addressing a large unmet clinical need.   It’s been an incredible week of insightful panels, discussions, and networking at LSI!   #LSIEurope #Medtech

See our CFO Alexander Goemans yesterday at LSI Europe during his 'Building Syndicates of Cross-Border Investors in Medtech Companies' panel.   It has been fantastic so far to listen and contribute to such high-level conversations with industry leaders in the medtech field.   We are excited to see what the rest of the week brings - if you are also in attendance and would like to connect with Alexander and our CEO Eliane Schutte, please reach out!   #LSIEurope24 #medtech

The countdown to LSI Europe is on - just one week left until I’ll be in Portugal representing @Xeltis alongside our CEO, Eliane Schutte.   I will be sharing my insights during a panel session: 🎤 Building Syndicates of Cross-Border Investors in Medtech Companies 📅 17 September ⌚ 15:45 - 16:25 CEST   If you'd like to connect directly, don’t hesitate to reach out!   #LSIEurope2024

Xeltis is gearing up for LSI Europe, now less than a week away!   Our CEO, Eliane Schutte, and CFO, Alexander Goemans, will be heading to Sintra, Portugal from September 16th-20th to take part in presentations and panels.   If you’re attending, don’t miss our sessions - check the agenda in the comments and make sure to join us!   Want to connect with a team member directly? Reach out, we'd love to hear from you.   See you in Portugal! ☀️ #LSIEurope2024

Honoured to visit the outstanding Bari Policlinico, led by Prof. Dr. Loreto Gesualdo, Chief of the Renal, Dialysis, and Transplantation Unit at University Hospital "Policlinico" of Bari, and esteemed Professor at the University of Bari Aldo Moro. The multidisciplinary team's dedication and the state-of-the-art infrastructure are driving innovative solutions for patient care. #RenalCare #VascularAccess #Hemodialysis

At Xeltis, we are dedicated to revolutionising the treatment of life-threatening diseases through our advanced vascular implants. In this presentation, our CEO, Eliane Schutte, provides an in-depth look at Xeltis' innovative pipeline, highlighting the impressive clinical data behind our lead product, #aXess. Don’t miss the opportunity to learn about how our regenerative, self-healing polymer implants support the natural development of living, long lasting tissue. We take great pride in the groundbreaking work we do at Xeltis, and we look forward to initiating our US pivotal trial for aXess in the coming months. The video is also available on our YouTube channel via the link in the comments below, subscribe while you're there!